Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Bought back 196,000 shares
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Comment by EbbFlow88on Jul 08, 2022 7:29am
169 Views
Post# 34810445

RE:RE:Bought back 196,000 shares

RE:RE:Bought back 196,000 shares
gudisgood wrote:
MrMugsy wrote:
Filed 2022-07-07 14:09
 
Tx date 2022-06-30		 $GUD
Knight Therapeutics Inc.		 Knight Therapeutics Inc.
1 - Issuer
Direct Ownership
Common Shares
38 - Redemption, retraction, cancellation, repurchase
-195,970 vol


Interesting, the buybacks have effectively stopped? I hope that's a sign of there being an attractive acquisition target. Perhaps they've found even better uses for the money. :)


The current NCIB should be maxed out by now as they were able to buy and cancel 10.6M shares. That expires around July 12-13, so we should see next week that they are renewing the NCIB for 2022.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities